متابعة
Mariann Harangi
Mariann Harangi
University of Debrecen Faculty of Medicine
بريد إلكتروني تم التحقق منه على belklinika.com
عنوان
عدد مرات الاقتباسات
عدد مرات الاقتباسات
السنة
The impact of obesity on the cardiovascular system‏
I Csige, D Ujvárosy, Z Szabó, I Lőrincz, G Paragh, M Harangi, S Somodi‏
Journal of diabetes research 2018 (1), 3407306, 2018‏
5902018
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)‏
AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ...‏
The Lancet 398 (10312), 1713-1725, 2021‏
2002021
Hypertension in thyroid disorders‏
E Berta, I Lengyel, S Halmi, M Zrínyi, A Erdei, M Harangi, D Páll, EV Nagy, ...‏
Frontiers in endocrinology 10, 482, 2019‏
1572019
Serum paraoxonase activity changes in uremic and kidney-transplanted patients‏
G Paragh, L Asztalos, I Seres, Z Balogh, L Löcsey, I Kárpáti, J Mátyus, ...‏
Nephron 83 (2), 126-131, 1999‏
1211999
Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage‏
M Harangi, I Seres, Z Varga, G Emri, Z Szilvássy, G Paragh, É Remenyik‏
European Journal of Clinical Pharmacology 60, 685-691, 2004‏
1112004
Association of chemerin with oxidative stress, inflammation and classical adipokines in non‐diabetic obese patients‏
P Fülöp, I Seres, H Lőrincz, M Harangi, S Somodi, G Paragh‏
Journal of cellular and molecular medicine 18 (7), 1313-1320, 2014‏
902014
Contribution of animal models to the understanding of the metabolic syndrome: a systematic overview‏
O Varga, M Harangi, IAS Olsson, AK Hansen‏
Obesity Reviews 11 (11), 792-807, 2010‏
862010
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?‏
Z Balogh, I Seres, M Harangi, P Kovacs, GY Kakuk, GY Paragh‏
Diabetes and Metabolism 27 (5; PART 1), 604-610, 2001‏
852001
The human paraoxonase‐1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters‏
HZ Mirdamadi, F Sztanek, Z Derdak, I Seres, M Harangi, G Paragh‏
British journal of clinical pharmacology 66 (3), 366-374, 2008‏
802008
Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels‏
P Koncsos, I Seres, M Harangi, I Illyés, L Józsa, F Gönczi, L Bajnok, ...‏
Pediatric research 67 (3), 309-313, 2010‏
712010
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease‏
G Paragh, I Seres, M Harangi, Z Balogh, L Illyes, J Boda, Z Szilvássy, ...‏
Diabetes & metabolism 29 (6), 613-618, 2003‏
712003
Determination of DNA damage induced by oxidative stress in hyperlipidemic patients‏
M Harangi, É Remenyik, I Seres, Z Varga, E Katona, G Paragh‏
Mutation Research/Genetic Toxicology and Environmental Mutagenesis 513 (1-2 …, 2002‏
672002
High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus‏
K Gaál, T Tarr, H Lőrincz, V Borbás, I Seres, M Harangi, P Fülöp, ...‏
Lipids in health and disease 15, 1-8, 2016‏
652016
Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia‏
G Paragh, D Tör’’ocsik, I Seres, M Harangi, L Illyés, Z Balogh, P Kovacs‏
Current medical research and opinion 20 (8), 1321-1327, 2004‏
622004
Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease‏
F Sztanek, I Seres, M Harangi, L Lőcsey, J Padra, GJR Paragh, L Asztalos, ...‏
Nephrology Dialysis Transplantation 27 (7), 2866-2872, 2012‏
552012
Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity‏
M Harangi, HZ Mirdamadi, I Seres, F Sztanek, M Molnár, A Kassai, ...‏
Translational Research 153 (4), 190-198, 2009‏
512009
Dynamic interplay between metabolic syndrome and immunity‏
G Paragh, I Seres, M Harangi, P Fülöp‏
Oxidative Stress and Inflammation in Non-communicable Diseases-Molecular …, 2014‏
502014
Orlistat increases serum paraoxonase activity in obese patients‏
M Audikovszky, G Pados, I Seres, M Harangi, P Fülöp, E Katona, L Illyés, ...‏
Nutrition, metabolism and cardiovascular diseases 17 (4), 268-273, 2007‏
502007
Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects‏
H Lőrincz, M Katkó, M Harangi, S Somodi, K Gaál, P Fülöp, G Paragh, ...‏
Clinical endocrinology 81 (3), 370-377, 2014‏
492014
The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation‏
P Szodoray, G Papp, B Nakken, M Harangi, M Zeher‏
Autoimmunity Reviews 9 (6), 459-464, 2010‏
472010
يتعذر على النظام إجراء العملية في الوقت الحالي. عاود المحاولة لاحقًا.
مقالات 1–20